Table 1.
Vaccination groups | Mean ± SD live L3s | Percent protection |
---|---|---|
pVAXBmVAL-1 DNA monovalent homologous | 12.2 ± 4.5 | 39.0% ± 1.7%** |
rBmVAL-1 protein monovalent homologous | 10.4 ± 3.1 | 48.0% ± 2.1%* |
pVAXBmVAL-1 DNA plus rBmVAL-1 monovalent heterologous | 9.2 ± 2.2 | 54.0% ± 3.1%* |
pVAXBmALT-2 DNA monovalent homologous | 9.8 ± 2.1 | 51.0% ± 2.5%* |
rBmALT-2 protein monovalent homologous | 7.0 ± 1.1 | 65.0% ± 4.2%* |
pVAXBmALT-2 DNA plus rBmALT-2 monovalent heterologous | 5.1 ± 0.5 | 74.5% ± 3.1%* |
pVAXBmVAL-1/ALT-2 DNA multivalent homologous | 8.6 ± 0.1 | 57.0% ± 2.2%* |
rBmVAL-1/rBmALT-2 protein multivalent homologous | 5.2 ± 1.1 | 74.0% ± 3.3%* |
pVAXBmVAL-1/BmALT-2 DNA plus rBmVAL-1/rBmALT-2 multivalent heterologous | 4.4 ± 0.4 | 82.0% ± 2.2%* |
pVAX + alum control | 20 ± 0 | 0% |
Notes: Significance
P < 0.01;
P < 0.05 compared with control.